Yichao Chen

TL;DR: It is shown that systemic delivery of paclitaxel (PTX) using the PEG2k-Fmoc-NLG nanocarrier leads to a significantly improved antitumour response in both breast cancer and melanoma mouse models.

TL;DR: DOX‐loaded POEG‐b‐PSSDas micelles were more effective in inhibiting the tumor growth and prolonging the survival rate in an aggressive murine breast cancer model and a micellar formulation co‐loaded with DOX and DAS provides an attractive strategy for effective combination of tumor targeted therapy and traditional chemotherapy.

TL;DR: The study suggests that PEG5K-Vitmin E2 may hold promise as an improved micellar formulation for in vivo delivery of anticancer agents such as PTX.

TL;DR: Systemic delivery of DOX via PSSN10 nanocarrier results in synergistic anti-tumor activity and a more immunoactive tumor microenvironment was observed in the mice treated with P SSN10 or DOX/PSSN10 micelles compared with the other treatment groups.

TL;DR: The antitumor activity of the PTX loaded PEG5K-FTS2(L) micelles in a syngeneic murine breast cancer model was found to be significantly higher than that of Taxol, which may be attributed to their preferential tumor accumulation and a possible synergistic effect between the carrier and the codelivered drug.